Voya Investment Management LLC Sells 17,760 Shares of Agios Pharmaceuticals, Inc. $AGIO

Voya Investment Management LLC cut its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 53.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,247 shares of the biopharmaceutical company's stock after selling 17,760 shares during the period. Voya Investment Management LLC's holdings in Agios Pharmaceuticals were worth $447,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of AGIO. PNC Financial Services Group Inc. lifted its holdings in shares of Agios Pharmaceuticals by 16.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock worth $105,000 after acquiring an additional 499 shares during the period. CWM LLC grew its position in shares of Agios Pharmaceuticals by 150.2% during the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 996 shares during the period. NewEdge Advisors LLC acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth approximately $40,000. Harbor Capital Advisors Inc. grew its position in shares of Agios Pharmaceuticals by 5.8% during the 1st quarter. Harbor Capital Advisors Inc. now owns 35,729 shares of the biopharmaceutical company's stock worth $1,047,000 after buying an additional 1,962 shares during the period. Finally, Victory Capital Management Inc. grew its position in shares of Agios Pharmaceuticals by 28.8% during the 1st quarter. Victory Capital Management Inc. now owns 8,784 shares of the biopharmaceutical company's stock worth $257,000 after buying an additional 1,964 shares during the period.

Analysts Set New Price Targets

Several research analysts recently weighed in on AGIO shares. HC Wainwright reissued a "buy" rating and set a $56.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, September 4th. Bank of America reduced their price objective on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Finally, Scotiabank reduced their price objective on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a research note on Monday, July 28th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $56.00.

Agios Pharmaceuticals Trading Up 6.3%

Shares of AGIO opened at $38.93 on Friday. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58. The company has a market cap of $2.26 billion, a price-to-earnings ratio of 3.54 and a beta of 0.87. The company's fifty day simple moving average is $37.44 and its 200 day simple moving average is $33.54.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). The business had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,085 shares of the business's stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $36.67, for a total transaction of $406,486.95. Following the completion of the transaction, the chief executive officer owned 123,528 shares of the company's stock, valued at approximately $4,529,771.76. The trade was a 8.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sarah Gheuens sold 11,914 shares of the company's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $37.99, for a total value of $452,612.86. Following the completion of the transaction, the insider directly owned 61,271 shares of the company's stock, valued at $2,327,685.29. This represents a 16.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,036 shares of company stock worth $1,369,980 in the last ninety days. Insiders own 4.30% of the company's stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.